Lonza Group Ag (OTC: LZAGY)
Lonza Group Ag Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Lonza Group Ag Company Info
Lonza Group AG is engaged in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate. The Biologics segment serves as contract development and manufacturing partner for biopharmaceuticals, catering customers for all clinical and commercial manufacturing needs throughout the product lifecycle. The Small Molecules segment offers small molecule drug substances and intermediates related services. The Cell and Gene segment includes the Cell and Gene Technologies and Bioscience businesses. The Capsule and Health Ingredients segment provides innovative capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical companies. The Corporate segment refers to finance and accounting, legal, communication, information technology, and human resources functions. The company was founded on October 27, 1897 and is headquartered in Basel, Switzerland.
News & Analysis
Should You Have Lonza Stock on Your Watchlist?
If it's stability you're looking for, probably so.
2 Best Pharma Stocks to Buy in November
The two pharma stocks offer investors the upside of a coronavirus vaccine with the peace of mind of century-old businesses.
Lonza Swipes a Top Roche Executive to Be Its Next CEO
Pierre-Alain Ruffieux will lead the contract development and manufacturing organization.
Moderna and Novavax are Making Strides in Advancing Novel Coronavirus Vaccine Research
The biotechnology companies creating COVID-19 vaccines should give hope to patients and investors. Moderna and Novavax are no exception.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.